Yüklüyor......
Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancer
PURPOSE: Anti-programmed death-1 (PD-1) receptor-based therapeutics improve survival in recurrent head and neck squamous cell carcinoma (HNSCC) patients but many do not benefit due to a low response rate. Herein, we identified EZH2 as a therapeutic target that enhanced tumor cell antigen presentatio...
Kaydedildi:
| Yayımlandı: | Clin Cancer Res |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6942613/ https://ncbi.nlm.nih.gov/pubmed/31562203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1351 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|